Idelalisib ± Bendamustine/Rituximab in Relapsed/Refractory CLL

December 5-8, 2015; Orlando, Florida
Combination idelalisib plus BR therapy significantly improved survival outcomes in patients with R/R CLL.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.54 MB
Released: December 17, 2015

Acknowledgements

Educational grant provided by:
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics
Takeda Oncology

Related Content

Ruxolitinib plus thalidomide achieved objective disease improvements in patients with myelofibrosis in phase II study from ASH 2018 reported by Clinical Care Options (CCO).

Released: December 11, 2018

Results from the CASSINI study of rivaroxaban for VTE prophylaxis in ambulatory patients with cancer from ASH 2018 reported by Clinical Care Options (CCO).

Released: December 11, 2018

Phase III RV-MM-PI-0752 study on optimizing lenalidomide/dexamethasone for elderly patients with newly diagnosed MM from ASH 2018 reported by Clinical Care Options (CCO).

Released: December 11, 2018

Data from phase III ECHELON-2 trial of brentuximab vedotin plus CHP in untreated CD30+ PTCL from ASH 2018, reported by Clinical Care Options (CCO).

Released: December 11, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?